ARCH Venture Partners — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Matthew Fust(Director)Kari Stefansson(Director)Joshua Pinto(Executive Officer)Maykin Ho(Director)Alaa Halawa(Director)Tamara Tompkins(Executive Officer)
Board seatRobert NelsenKristina Burow· per SEC Form D
BiotechSan Francisco, US
Thomas Hecht(Director)Sung Lee(Executive Officer, Director)Johanna Friedl-Naderer(Director)Natascha Schill(Executive Officer, Director)Vanina de Verneuil(Executive Officer)
Board seatGeorge Scangos· per SEC Form D · $400K raise · filed Apr 2023
HealthtechBethesda, US
Stephanie Lovell(Director)Rahul Rajkumar(Executive Officer, Director)Bryan Roberts(Director)Vivian Riefberg(Director)Robert Kocher(Director)
Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.
AI & Machine LearningBiotechWatertown, US
Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Matthew Patterson(Director)Scott Biller(Director)Heather Wasserman(Executive Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.